In an adult with osteoporosis at very high fracture risk (prior fragility fracture, T‑score ≤ ‑3.5, or ≥30% 10‑year major osteoporotic fracture risk) and optimized calcium and vitamin D intake, when should anabolic therapy be started, which agents are first‑line, and what monitoring and post‑treatment anti‑resorptive transition are recommended?

Anabolic Therapy for Very High-Risk Osteoporosis

For adults with osteoporosis at very high fracture risk, anabolic agents (teriparatide, abaloparatide, or romosozumab) should be started immediately after optimizing calcium and vitamin D, and must be followed by mandatory transition to an antiresorptive agent to prevent rebound bone loss. 1

Defining Very High Fracture Risk

Very high fracture risk is established by any one of the following criteria 2, 1:

• Prior osteoporotic (fragility) fracture
• BMD T-score ≤ -3.5 at hip or spine
• FRAX 10-year major osteoporotic fracture risk ≥ 30%
• FRAX 10-year hip fracture risk ≥ 4.5%
• High-dose glucocorticoid exposure (≥30 mg/day for >30 days or cumulative ≥5 g/year)

Pre-Treatment Requirements

Before initiating anabolic therapy, ensure 2, 1:

• Calcium intake: 1,000–1,200 mg/day from diet plus supplements
• Vitamin D: 600–800 IU/day targeting serum 25(OH)D ≥ 30 ng/mL (some guidelines suggest ≥20 ng/mL is adequate)
• Dental evaluation: Complete any invasive dental procedures before starting therapy to minimize osteonecrosis risk
• Baseline assessment: BMD with vertebral fracture assessment (VFA) or spine X-rays within 6 months of treatment initiation

First-Line Anabolic Agent Selection

The 2023 ACR guideline conditionally recommends anabolic agents over antiresorptive therapy for very high-risk patients 2. The choice among anabolic agents depends on specific clinical factors:

Teriparatide (PTH 1-34)

• Indication: Very high-risk patients, particularly those with recent vertebral fractures 3
• Evidence: Compared to alendronate in glucocorticoid-induced osteoporosis, teriparatide increased lumbar and hip BMD and decreased vertebral (but not nonvertebral) fractures at 36 months 2
• Dosing: Daily subcutaneous injection
• Duration: Up to 24 months maximum lifetime exposure
• Key limitation: Bone anabolic effect is blunted if given after prior antiresorptive therapy 2

Abaloparatide (PTHrP analog)

• Indication: Very high-risk patients based on BMD data 2
• Status: Considered appropriate first-line treatment but evidence is weaker than teriparatide 2
• Dosing: Daily subcutaneous injection
• Duration: Up to 18 months
• Caution: Long-term safety in humans not yet fully established 4

Romosozumab (sclerostin inhibitor)

• Indication: Very high-risk patients, particularly those intolerant of other agents 2, 1
• Advantage: Monthly subcutaneous injection (better adherence than daily injections)
• Duration: 12 months only
• Critical safety concern: Increased risk of myocardial infarction, stroke, and cardiovascular death 2, 1. Contraindicated in patients with prior MI or stroke within 1 year

When Anabolic Agents Are Not Suitable

If anabolic therapy is contraindicated or declined, the treatment hierarchy for very high-risk patients is 1:

1. Oral bisphosphonates (alendronate or risedronate) – strongly recommended as first alternative 2
2. Denosumab 60 mg subcutaneous every 6 months – conditionally recommended, preferred if creatinine clearance <60 mL/min 1
3. IV bisphosphonates (zoledronic acid) – conditionally recommended, higher infusion-related adverse event risk 1

Mandatory Sequential Antiresorptive Transition

This is the most critical pitfall to avoid: Failure to transition from anabolic therapy to an antiresorptive agent results in rapid bone loss and increased vertebral fracture risk 2, 1.

After Teriparatide or Abaloparatide

• Timing: Start antiresorptive immediately upon completion of anabolic course 2, 4
• Agent options: Bisphosphonate (preferred) or denosumab 2
• Rationale: Discontinuation leads to gradual BMD loss over 12–18 months without subsequent therapy 2

After Romosozumab

• Timing: Start antiresorptive immediately after 12-month course 1
• Agent: Bisphosphonate or denosumab 1
• Special consideration: If denosumab is used after romosozumab, it must subsequently be followed by bisphosphonate therapy 2

After Denosumab (if used first-line)

• Critical timing: If denosumab is stopped for >6 months, vertebral fractures can occur as early as 7–9 months after the last dose 2
• Transition strategy: Start bisphosphonate 6–7 months after last denosumab dose for at least 1 year 2

Monitoring During and After Anabolic Therapy

The 2023 ACR guideline endorses regular monitoring, contrasting with earlier recommendations 1:

• BMD with VFA or spine X-ray: Every 1–2 years to assess treatment response 2, 1
• Bone turnover markers: Weakly recommended to assess adherence to subsequent antiresorptive therapy 5
• Reassess fracture risk: After completing anabolic course and during antiresorptive maintenance

Special Populations

Glucocorticoid-Induced Osteoporosis

• Assessment timing: Within 6 months of starting ≥2.5 mg/day prednisone for >3 months 2, 1
• FRAX adjustment: For doses >7.5 mg/day, multiply MOF risk by 1.15 and hip fracture risk by 1.20 2, 1
• Treatment: Same anabolic-first approach for very high-risk patients 2

Renal Impairment (CrCl <60 mL/min)

• Preferred agents: Denosumab, teriparatide, abaloparatide, or romosozumab (no dose adjustment needed) 2, 1
• Avoid: Bisphosphonates when CrCl <35 mL/min 2
• Caution: Denosumab may cause prolonged severe hypocalcemia; ensure adequate calcium/vitamin D supplementation 2

Adults <40 Years

• Very high risk defined by: Prior fracture or high-dose glucocorticoid exposure 1
• Treatment: Oral bisphosphonates conditionally recommended over calcium/vitamin D alone 2, 1
• Pregnancy: Avoid bisphosphonates in women of childbearing potential due to teratogenic risk 1

Common Pitfalls to Avoid

1. Omitting sequential therapy – This is the single most dangerous error; always plan the transition before starting anabolic therapy 2, 1
2. Starting anabolic therapy after bisphosphonates – The anabolic effect is significantly blunted 2
3. Inadequate calcium/vitamin D – Must be optimized before and maintained during all osteoporosis therapy 2, 1
4. Ignoring cardiovascular history with romosozumab – Absolute contraindication if MI or stroke within past year 1
5. Extending denosumab intervals – Must maintain every 6-month dosing; extending intervals increases fracture risk 1
6. Stopping denosumab without bridging – Leads to rebound osteolysis and vertebral fractures 2, 1